
News
Filter Results
Displaying 181–190 of 508
-
Oct 8, 2021
Foundation Hosts Workshop on USH1B Research and Therapy Development
Emerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Oct 7, 2021
Covid Revealed What Science Can Do When Funding is Found
‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
-
Oct 4, 2021
RD Fund Appoints Tony Adamis, MD to Board of Directors
The RD Fund announces the appointment of Anthony (Tony) Adamis, MD, to its board of directors.
-
Sep 30, 2021
The emerging treatment targets a specific mutation (c.2991+1655A>G in Intron 26) of the gene CEP290 which causes Leber congenital amaurosis 10 (LCA 10)
-
Sep 28, 2021
RD Fund Launches Opus Genetics to Advance Gene Therapies for Inherited Retinal Diseases
First two programs are for Leber congenital amaurosis: LCA5-lebercillin and LCA13-RDH12
-
Sep 27, 2021
Foundation Awarded 21 New Grants in FY2021 Totaling More than $14.2 Million
Current research portfolio is comprised of nearly 100 projects at prominent institutions around the world
-
Sep 24, 2021
MeiraGTx and Janssen Recruiting for Phase 3 XLRP Gene Therapy Clinical Trial
Visit www.LUMEOSstudy.com for more information about trial
-
Sep 22, 2021
Initial programs will focus on treatments for rare pediatric blinding conditions. Company formed to advance the work of scientific cofounders Dr. Jean Bennett, Junwei Sun and Dr. Eric Pierce.
-
Sep 21, 2021
Course Title: A Review and Comparison of Different Forms of Age-Related and Inherited Macular Degenerations
-
Sep 10, 2021
Apellis to Seek FDA Approval of its Dry AMD Drug
Known as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial